Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped down before the market opened on Thursday. The stock had previously closed at $41.99, but opened at $38.10. Zealand Pharma A/S shares last traded at $38.10, with a volume of 1,000 shares traded.

Analyst Ratings Changes

ZLDPF has been the topic of a number of recent research reports. Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, September 11th. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Barclays cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Finally, Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Zealand Pharma A/S Trading Down 12.7%

The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. The firm has a market cap of $2.73 billion, a PE ratio of 6.32 and a beta of 0.89. The company’s 50 day moving average price is $46.91 and its 200 day moving average price is $46.38.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.